期刊文献+

中国加入兽药注册技术要求国际协调会(VICH)可行性与利弊分析

The Feasibility and Advantages and Disadvantages of China′s Accession to VICH
下载PDF
导出
摘要 介绍了兽药注册技术要求国际协调会(VICH)基本情况,分析了我国兽药注册技术要求与VICH指南的差异,并从两者兽药注册规则的角度,研究我国加入VICH的可行性及利弊问题,以期为决策提供参考。 This paper introduces the basic situation of VICH,analyzes the differences between China's technical requirements of veterinary drug registration and VICH guidelines,and studies the feasibility and advantages and disadvantages of joining VICH from the perspective of both veterinary drug registration rules,in order to provide reference for decision-making.
作者 顾进华 梁先明 曲鸿飞 汪霞 高光 GU Jin-hua;LIANG Xian-ming;QU Hong-fei;WANG Xia;GAO Guang(China Institute Veterinary Drug Control, Beijing 100081, China)
出处 《中国兽药杂志》 2020年第9期72-76,共5页 Chinese Journal of Veterinary Drug
关键词 兽药 注册 兽药注册技术要求国际协调会 利弊 veterinary drug registration Veterinary International Conference on Harmonization(VICH) advantages and disadvantages
  • 相关文献

参考文献7

二级参考文献58

  • 1上海市食品药品安全研究中心课题组.国外药品上市前注册制度研究[J].上海食品药品监管情报研究,2011(6):1-6. 被引量:4
  • 2董江萍,刘璐,张象麟.中美两国药品注册工作时限管理的比较[J].中国新药杂志,2005,14(1):4-7. 被引量:3
  • 3Slate Food and Drug Administration, Center for Drug Evaluation. Guidance for Industry: bioavailability and bioequivalence studies for chemical drug products. [ EB/OL]. (2009-12-17) http://www, cde. org. cn/zdyz, do? method = largePage&id = 2066.
  • 4JIANGWL YUXQ.Review of the quality evaluation of generics in US.中国处方药,2008,79(10):43-46.
  • 5ICH Hannonised Tripartite Guideline: Pharmaceutical Development Q8(112) [EB/OL]. (2010-03-19) http://www, ich. org/ LOB/media/MEDIA4986. pdf.
  • 6JIANGWL YUXQ.Introduction of the evaluation of generics and summary of quality evaluation of drug sabstances in US.中国处方药,2008,79(10):39-42.
  • 7HUOXM.Disscussion about how to improve quality of chemical generic drugs in view of registration .中国执业药师,2008,5(9):36-37.
  • 8WUZ.Changes of drug evaluation in the two years and trend in future .中国新药杂志,2009,18(20):1923-1925.
  • 9US Food and Drug Administration, Critical Path Opportunities for Generic Drugs[ EB/OL]. (2009-06-18) http://www, fda. gov/ ScienceResearch/SpecialTopics/CriticalPathlnitiative/Critical - PathOpportunitiesReports/ucm077250. htm#quality.
  • 10TGA. Australian Regulatory Guidelines for Prescription Medicines,APPENDIX 15 : Biopharmaceutical Studies [ EB/OL ] . ( 2010-3-30 ) http ://www. tga. gov. au/pmeds/argpmap 15. pdf.

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部